Secretome Therapeutics

Secretome Therapeutics is developing first-in-class therapies derived from neonatal mesenchymal stem cells (nMSC) for the treatment and prevention of underserved diseases. Our lead product, STM-01, is a novel secretome in development for the prevention of cisplatin-induced acute kidney injury.